Membrane proteins are essential for cell functions such as maintaining cellular physiological processes, playing crucial roles in substance transport, signal transduction, and cell recognition. They constitute approximately 25% of the total proteome encoded by the human genome. Currently, membrane protein targets account for over 60% of known drug targets and over 90% of antibody drug targets, such as BCMA, GPRC5D, CCR8, among others. Despite their critical roles, membrane protein preparation is highly challenging, particularly for multi-pass transmembrane proteins.
Due to hydrophobic regions across multiple transmembrane domains, these proteins tend to aggregate in vitro, making it difficult to maintain their natural structures, thereby affecting their normal functions. Therefore, maintaining the native conformation of membrane proteins in vitro remains a crucial issue in the expression and purification process. Additionally, improving protein purity is also a significant challenge to address.
Nanodisc technology is currently one of the best solutions for purifying membrane proteins under native conditions. More information about Nanodisc>>
Membrane Protein Paris 2024 Overview
The SMALP network aims to provide a platform for scientists and companies interested in membrane nanodisc preparation, focusing mainly on biological research and drug discovery. Membrane Protein Paris 2024 is an online conference jointly organized by the SMALP network and APPICOM & ISC-PIF on Oct. 14. This conference brings together scientists specializing in biochemistry, biophysics, polymer chemistry, molecular biology, and cell biology to explore the latest developments related to biological membranes.
At this conference, Dr. Ma Donghui, CEO of DIMA Biotech, will introduce our proprietary DiMProTM membrane protein preparation platform – Synthetic Nanodisc, along with DIMA’s range of in-stock membrane protein products.
About DIMA
DIMA Biotech is the world’s only provider of over 500 in-stock synthetic Nanodisc proteins. These proteins, derived from the human HEK293 cell expression system, maintain their native structure and function as full-length multi-pass membrane proteins. They are crucial tools in various research fields, including cryo-EM, therapeutic antibody development, and small molecule screening. DIMA’s in-stock multi-pass membrane proteins assist researchers in overcoming challenges in current membrane protein expression and purification, facilitating downstream functional analysis.
Additionally, to ensure stability during transportation and long-term storage, all DIMA’s membrane protein products are shipped as lyophilized powder and undergo rigorous functional testing for each new production batch.
